The Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia (SURVIVE-VT) trial compares the efficacy and safety of catheter ablation versus antiarrhythmic drugs (AAD) as first-line therapy in patients with implantable cardioverter defibrillators (ICD) who present with symptomatic ventricular tachycardias (VT).

The ongoing COVID-19 pandemic has challenged health care systems worldwide and has brought to the forefront the limitations of providing high-quality health care under system stress.

There has been significant progress in our ability to identify future risk of development of heart failure (HF).

The Benefit of P2Y12 Inhibitor Pre-treatment

Bioprosthetic aortic valves are increasingly used for surgical aortic valve replacement (SAVR) in patients with aortic stenosis to avoid use of oral anticoagulation therapy (OAC).